Vanita Aroda1, Theodore P Ciaraldi1, Sang-Ah Chang1, Michael H Dahan2, R Jeffrey Chang2, Robert R Henry3. 1. VA San Diego Healthcare System, San Diego, California; Department of Medicine, University, San Diego, La Jolla, California. 2. Department of Reproductive Medicine, University of California, San Diego, California. 3. VA San Diego Healthcare System, San Diego, California; Department of Medicine, University, San Diego, La Jolla, California. Electronic address: rrhenry@vapop.ucsd.edu.
Abstract
OBJECTIVE: To evaluate serum adiponectin levels and organization into multimers in women with polycystic ovary syndrome (PCOS) and assess relationships between adiponectin, glucose tolerance, and insulin resistance. DESIGN: In vivo and in vitro study. SETTING: Outpatient clinic at university and Veterans hospitals in the United States and university laboratory. PATIENT(S): Thirty-one obese women with PCOS and six age- and body mass index (BMI)-matched normal cycling control subjects. INTERVENTION(S): All subjects studied in the fasting state. MAIN OUTCOME MEASURE(S): A 75-g oral glucose tolerance test (OGTT), hyperinsulinemic/euglycemic clamp, circulating adiponectin levels, adipocyte adiponectin content, and organization of adiponectin into multimeric forms. RESULT(S): Whole body insulin action (glucose disposal rate, 5.61 +/- 2.90 vs. 8.79 +/- 0.81 mg/kg/min, PCOS and control) and adiponectin levels (9.5 +/- 0.7 7 vs. 17.4 +/- 1 microg/mL, PCOS vs. control) were significantly reduced in the subjects with PCOS. There were significant correlations between glucose tolerance, insulin action, and circulating adiponectin levels in all subjects. The content of adiponectin protein was reduced in subcutaneous adipocytes from subjects with PCOS (252 +/- 31 vs. 388 +/- 58 arbitrary units/10 microg protein). Subjects with PCOS had less of their circulating adiponectin organized into high molecular weight (HMW) multimeric complexes. Glucose-intolerant subjects with PCOS also had less intracellular HMW adiponectin. CONCLUSION(S): Both circulating adiponectin levels and the portion present as the most active HMW form are reduced in PCOS, with differences related to the degree of glucose intolerance and insulin resistance.
OBJECTIVE: To evaluate serum adiponectin levels and organization into multimers in women with polycystic ovary syndrome (PCOS) and assess relationships between adiponectin, glucose tolerance, and insulin resistance. DESIGN: In vivo and in vitro study. SETTING:Outpatient clinic at university and Veterans hospitals in the United States and university laboratory. PATIENT(S): Thirty-one obesewomen with PCOS and six age- and body mass index (BMI)-matched normal cycling control subjects. INTERVENTION(S): All subjects studied in the fasting state. MAIN OUTCOME MEASURE(S): A 75-g oral glucose tolerance test (OGTT), hyperinsulinemic/euglycemic clamp, circulating adiponectin levels, adipocyte adiponectin content, and organization of adiponectin into multimeric forms. RESULT(S): Whole body insulin action (glucose disposal rate, 5.61 +/- 2.90 vs. 8.79 +/- 0.81 mg/kg/min, PCOS and control) and adiponectin levels (9.5 +/- 0.7 7 vs. 17.4 +/- 1 microg/mL, PCOS vs. control) were significantly reduced in the subjects with PCOS. There were significant correlations between glucose tolerance, insulin action, and circulating adiponectin levels in all subjects. The content of adiponectin protein was reduced in subcutaneous adipocytes from subjects with PCOS (252 +/- 31 vs. 388 +/- 58 arbitrary units/10 microg protein). Subjects with PCOS had less of their circulating adiponectin organized into high molecular weight (HMW) multimeric complexes. Glucose-intolerant subjects with PCOS also had less intracellular HMW adiponectin. CONCLUSION(S): Both circulating adiponectin levels and the portion present as the most active HMW form are reduced in PCOS, with differences related to the degree of glucose intolerance and insulin resistance.
Authors: Aimin Xu; Kok Weng Chan; Ruby L C Hoo; Yu Wang; Kathryn C B Tan; Jialiang Zhang; Baoying Chen; Michael C Lam; Cynthia Tse; Garth J S Cooper; Karen S L Lam Journal: J Biol Chem Date: 2005-03-09 Impact factor: 5.157
Authors: Susan A Phillips; Theodore P Ciaraldi; Alice P S Kong; Rahil Bandukwala; Vanita Aroda; Leslie Carter; Sunita Baxi; Sunder R Mudaliar; Robert R Henry Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Joseph G Yu; Sandrine Javorschi; Andrea L Hevener; Yolanta T Kruszynska; Rodney A Norman; Madhur Sinha; Jerrold M Olefsky Journal: Diabetes Date: 2002-10 Impact factor: 9.461
Authors: Edmond P Wickham; Kai I Cheang; John N Clore; Jean-Patrice Baillargeon; John E Nestler Journal: Metabolism Date: 2010-03-31 Impact factor: 8.694
Authors: Suk Yu Yau; Ang Li; Ruby L C Hoo; Yick Pang Ching; Brian R Christie; Tatia M C Lee; Aimin Xu; Kwok-Fai So Journal: Proc Natl Acad Sci U S A Date: 2014-10-20 Impact factor: 11.205
Authors: Theodore P Ciaraldi; Vanita Aroda; Sunder Mudaliar; R Jeffrey Chang; Robert R Henry Journal: J Clin Endocrinol Metab Date: 2008-10-14 Impact factor: 5.958
Authors: Vanita R Aroda; Theodore P Ciaraldi; Paivi Burke; Sunder Mudaliar; Paul Clopton; Susan Phillips; R Jeffrey Chang; Robert R Henry Journal: J Clin Endocrinol Metab Date: 2008-11-04 Impact factor: 5.958
Authors: Susan A Phillips; Jacqueline Kung; Theodore P Ciaraldi; Charles Choe; Louis Christiansen; Sunder Mudaliar; Robert R Henry Journal: Am J Physiol Endocrinol Metab Date: 2009-07-21 Impact factor: 4.310
Authors: Shali Mazaki-Tovi; Adi L Tarca; Edi Vaisbuch; Juan Pedro Kusanovic; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Zhong Dong; Sonia S Hassan; Roberto Romero Journal: J Perinat Med Date: 2016-10-01 Impact factor: 1.901